Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis
BackgroundCoronavirus disease 2019 (COVID-19) have brought great disaster to mankind, and there is currently no globally recognized specific drug or treatment. Severe COVID-19 may trigger a cytokine storm, manifested by increased levels of cytokines including interleukin-17 (IL-17), so a new strateg...
Main Authors: | Meitong Liu, Huijuan Wang, Lu Liu, Saijin Cui, Xiangran Huo, Zhuoyun Xiao, Yaning Zhao, Bin Wang, Guoqiang Zhang, Na Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1046352/full |
Similar Items
-
Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
by: Gianluca Avallone, et al.
Published: (2023-02-01) -
On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study
by: Pim Sermsaksasithorn, et al.
Published: (2022-10-01) -
Immunohistochemical demonstration of interleukin-17 positivity in skin biopsy specimens of patients with chronic plaque psoriasis and its correlation with severity of psoriasis and associated metabolic syndrome and cardiovascular changes
by: Madivalara Yallappa Suparna, et al.
Published: (2022-01-01) -
Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
by: Marie-Astrid Boutet, et al.
Published: (2018-02-01) -
Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
by: Yu-Huei Huang, et al.
Published: (2023-02-01)